Incretins and incretin analogs have a neuroprotective impact on the brain, as demonstrated by the ability of long-acting liraglutide to restore the distribution of insulin receptors on cell membranes in a rat model with AD (APPSWE/PS1dE9), hence alleviating insulin signaling abnormalities. The gene discussed is GCG; the disease is Alzheimer disease.